Evaluation of EGFR, KRAS, and TP53 mutations as predictive of disease recurrence in resected early non-small cell lung carcinomas (NSCLCs)
Authors:
- Jair BarJBJair Bar
- Maya DamianovichMDMaya Damianovich
- Goni Hout SiloniGSGoni Hout Siloni
- Erel DarEDErel Dar
- Yehudit CohenYCYehudit Cohen
- Oranit ZadokOZOranit Zadok
- Yoram CohenYCYoram Cohen
- Marina PerelmanMPMarina Perelman
- Iris BarshackIBIris Barshack
- Ronit I YardenRYRonit I Yarden
- David SimanskyDSDavid Simansky
- Alon Ben NunANAlon Ben Nun
- 28 February 2014
- journal article
- Published by Springer Nature in memo - Magazine of European Medical Oncology
- Vol. 7 (1) , 10-15
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant DiseaseJournal of Clinical Oncology, 2013
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neckHead & Neck Oncology, 2011
- CHFR hypermethylation and EGFR mutation are mutually exclusive and exhibit contrastive clinical backgrounds and outcomes in non‐small cell lung cancerInternational Journal of Cancer, 2010
- Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung AdenocarcinomaJournal of Thoracic Oncology, 2009
- Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung AdenocarcinomaJournal of Thoracic Oncology, 2008
- Prognostic and Predictive Importance of p53 and RAS for Adjuvant Chemotherapy in Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2007
- High-throughput oncogene mutation profiling in human cancerNature Genetics, 2007
- Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With ErlotinibJournal of Clinical Oncology, 2005
- Assessing TP53 status in human tumours to evaluate clinical outcomeNature Reviews Cancer, 2001